The impact of endotrophin on the progression of chronic liver disease

[1]  Chang-Woo Lee,et al.  Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma , 2020, Experimental & Molecular Medicine.

[2]  Wenyu Lin,et al.  Dexmedetomidine promotes the progression of hepatocellular carcinoma through hepatic stellate cell activation , 2020, Experimental & Molecular Medicine.

[3]  P. Lønning,et al.  Human endotrophin as a driver of malignant tumor growth. , 2019, JCI insight.

[4]  J. Choi,et al.  COL6A3‐derived endotrophin links reciprocal interactions among hepatic cells in the pathology of chronic liver disease , 2018, The Journal of pathology.

[5]  Meilan K. Han,et al.  An airway epithelial IL-17A response signature identifies a steroid-unresponsive COPD patient subgroup , 2018, The Journal of clinical investigation.

[6]  C. Feldman.  Faculty Opinions recommendation of Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. , 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[7]  S. Yoo,et al.  Leucrose, a Sucrose Isomer, Suppresses Hepatic Fat Accumulation by Regulating Hepatic Lipogenesis and Fat Oxidation in High-fat Diet-induced Obese Mice , 2018, Journal of cancer prevention.

[8]  H. Sone,et al.  Transgenic Mice Overexpressing SREBP-1a in Male ob/ob Mice Exhibit Lipodystrophy and Exacerbate Insulin Resistance , 2018, Endocrinology.

[9]  Li Li,et al.  Role of COL6A3 in colorectal cancer , 2018, Oncology reports.

[10]  P. Iyengar,et al.  Adipocyte Xbp1s overexpression drives uridine production and reduces obesity , 2018, Molecular metabolism.

[11]  Xiangmei Chen,et al.  CRISPR/Cas9-mediated p53 and Pten dual mutation accelerates hepatocarcinogenesis in adult hepatitis B virus transgenic mice , 2017, Scientific Reports.

[12]  M. Karsdal,et al.  Serum endotrophin, a type VI collagen cleavage product, is associated with increased mortality in chronic kidney disease , 2017, PloS one.

[13]  P. Scherer,et al.  VEGF-A–Expressing Adipose Tissue Shows Rapid Beiging and Enhanced Survival After Transplantation and Confers IL-4–Independent Metabolic Improvements , 2017, Diabetes.

[14]  B. Becattini,et al.  JNK at the crossroad of obesity, insulin resistance, and cell stress response , 2016, Molecular metabolism.

[15]  Ashutosh Kumar Singh,et al.  Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2016, The Lancet.

[16]  R. Weiskirchen,et al.  Lipocalin 2 (LCN2) Expression in Hepatic Malfunction and Therapy , 2016, Front. Physiol..

[17]  Kalyani V. P. Guntur,et al.  Reduced expression of collagen VI alpha 3 (COL6A3) confers resistance to inflammation‐induced MCP1 expression in adipocytes , 2016, Obesity.

[18]  R. Schwabe,et al.  Serum Amyloid A Induces Inflammation, Proliferation and Cell Death in Activated Hepatic Stellate Cells , 2016, PloS one.

[19]  M. Karsdal,et al.  Serum endotrophin identifies optimal responders to PPARγ agonists in type 2 diabetes , 2016, Diabetologia.

[20]  J. McDonald,et al.  Targeted Induction of Ceramide Degradation Leads to Improved Systemic Metabolism and Reduced Hepatic Steatosis. , 2015, Cell metabolism.

[21]  M. Claussnitzer,et al.  COL6A3 expression in adipocytes associates with insulin resistance and depends on PPARγ and adipocyte size , 2014, Obesity.

[22]  J. Varga,et al.  Endotrophin triggers adipose tissue fibrosis and metabolic dysfunction , 2014, Nature Communications.

[23]  Zheng Zhang,et al.  The role of neutrophils in the development of liver diseases , 2014, Cellular and Molecular Immunology.

[24]  P. Scherer,et al.  Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumours , 2013, EMBO molecular medicine.

[25]  P. Scherer,et al.  Adipocyte-derived endotrophin promotes malignant tumor progression. , 2012, The Journal of clinical investigation.

[26]  S. Phipps,et al.  The activation of the receptor for advanced glycation end products (RAGE) contributes to the induction of Hdm-specific T(h)2 responses , 2012 .

[27]  Derek Y. Chiang,et al.  A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma , 2009, Nature Biotechnology.

[28]  A. Suzuki,et al.  Non‐alcoholic steatohepatitis and hepatocellular carcinoma: Lessons from hepatocyte‐specific phosphatase and tensin homolog (PTEN)‐deficient mice , 2007, Journal of Gastroenterology and Hepatology.

[29]  P. Socha,et al.  Nonalcoholic fatty liver disease as a feature of the metabolic syndrome. , 2007, Roczniki Panstwowego Zakladu Higieny.

[30]  H. Sone,et al.  Transgenic mice overexpressing SREBP-1a under the control of the PEPCK promoter exhibit insulin resistance, but not diabetes. , 2005, Biochimica et biophysica acta.

[31]  F. Kinjo,et al.  Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. , 2005, World journal of gastroenterology.

[32]  R. Hammer,et al.  Overexpression of Sterol Regulatory Element-binding Protein-1a in Mouse Adipose Tissue Produces Adipocyte Hypertrophy, Increased Fatty Acid Secretion, and Fatty Liver* , 2003, Journal of Biological Chemistry.

[33]  G. Marchesini,et al.  Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. , 2001, Diabetes.

[34]  D. Schuppan,et al.  Prediction of liver fibrosis according to serum collagen VI level in children with cystic fibrosis. , 1997, New England Journal of Medicine.

[35]  R. Hammer,et al.  Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. , 1997, The Journal of clinical investigation.

[36]  R. Hammer,et al.  Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. , 1996, The Journal of clinical investigation.

[37]  H. Tsukuma,et al.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease. , 1993, The New England journal of medicine.

[38]  T. Dragani,et al.  Major Urinary Protein as a Negative Tumor Marker in Mouse Hepatocarcinogenesis , 1989, Molecular carcinogenesis.